AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01381523 — intervention group
Intervention type: DRUG
Intervention: Single-entity oral triptans
Description: Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
Study NCT01666522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
Study NCT01666522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
Study NCT01666522 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
Study NCT01666522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
Study NCT04453956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the assistance of EndoAngel's polyp detection function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's polyp detection function,which can remind endoscopists of the location of the polyp.
Study NCT04453956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy with the assistance of EndoAngel's quality monitoring function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's quality monitoring function,which can monitor the withdrawal speed of the endoscope.
Study NCT04453956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Colonoscopy without the assistance of EndoAngel's any function.
Description: Patient in this group will receive colonoscopy with assistance of EndoAngel's both functions.
Study NCT02143271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK7580
Description: Oral administration
Study NCT00136604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax ACWY
Description: GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
Study NCT00136604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
Study NCT00136604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: Wyeth's MenC CRM197 conjugated vaccine, Meningitec
Study NCT03004248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins, Type A
Description: Intramuscular Injection
Study NCT02798614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10-day cast
Description: Removal of plaster cast fixation 10 days after reduction
Study NCT01309893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Lens
Description: Lenses worn on a daily wear basis for one week
Study NCT02408770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: selective progesterone receptor modulator
Study NCT01733693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
Study NCT01733693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
Study NCT00972257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with dorzolamide/timolol
Description: 24-hour IOP control with the two fixed combinations
Study NCT00972257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with brimonidine/timolol
Description: 24-hour pressure control with brimonidine/timolol
Study NCT04614272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prayer
Description: Prayer is a non-pharmaceutical method of pain management and a form of alternative medicine.
Study NCT04614272 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Reading a poem
Description: Reading is a distraction tool for pain management
Study NCT04212065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine
Description: To improve compliance with medication assisted therapy, decrease relapse and neonatal abstinence syndrome, we propose a randomized control trial of long acting subcutaneous buprenorphine compared to short acting sublingual buprenorphine/naloxone administration in pregnant and lactating women.
Study NCT03586232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arnica Montana
Description: Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
Study NCT03586232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bromelain
Description: Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
Study NCT03586232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A pharmacologically inert preparation
Study NCT03586232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pharmacologically inert preparation
Study NCT03384485 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: antiphospholipid syndrome
Description: blood test for enzyme test,plasma and Lys-3-3 plasma
Study NCT01309893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Lens
Description: Lenses worn on a daily wear basis for one week
Study NCT01309893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua lens
Description: Lenses worn on a daily wear basis for one week
Study NCT01309893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Optix Aqua lens
Description: Lenses worn on a daily wear basis for one week
Study NCT00327470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaptanib Sodium 0.3 mg
Description: Pegaptanib Sodium dosed every 6 weeks in affected eye.
Study NCT04397887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-surgical varicocelectomy
Description: Sub-inguinal micro-surgical varicocelectomy
Study NCT02576834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Services as usually provided in the community
Study NCT02576834 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Services as Usual
Description: Services as usually provided in the community
Study NCT01648179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (mesylate salt) Powder for Injection
Description: 1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
Study NCT01648179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (freebase) tablets
Description: 500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
Study NCT01648179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (mesylate salt) Powder for Oral Solution
Description: 1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
Study NCT01648179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 (freebase) tablets FED
Description: Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
Study NCT03518164 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allograft
Description: Bone graft
Study NCT01412918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Inhibitor™ Tinnitus Masking Device
Description: The Inhibitor™ Tinnitus Masking Device
Study NCT01690338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vecuronium Bromide
Description: Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
Study NCT01690338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
Study NCT01690338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisatracurium
Description: Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
Study NCT03900962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Description: Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets.
Study NCT03900962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking intervention
Description: After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
Study NCT05301712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 5.0mg/5ml
Description: * Initial dose: 4mg, Intravenous injection~* Continuous dose: 8mg(mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4mg+8mg/day\*7=60mg
Study NCT05301712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 45mg/5ml
Description: * Initial dose: 4ml, Intravenous injection~* Continuous dose: 8ml (mixed with 1000ml of 5% Dextrose water or saline solution) per day, Intravenous infusion for 7days~* Total dose: 4ml+8ml/day\*7=60ml
Study NCT02355977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: Periocline dental ointment
Study NCT02544984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Study NCT03398915 — intervention group
Intervention type: PROCEDURE
Intervention: Transpedicular Instrumentation
Description: Transpedicular screw placement and instrumentation
Study NCT02927639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyDiaText
Description: The intervention will consist of daily text messages sent to the subject's personal mobile device.
Study NCT03006757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture base
Study NCT00586989 — intervention group
Intervention type: PROCEDURE
Intervention: Upper endoscopy with biopsy
Description: Endoscopy with biopsy 6 weeks after the initial endoscopy
Study NCT02275143 — intervention group
Intervention type: RADIATION
Intervention: CT TAP Scan
Description: Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
Study NCT04340063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training performed on a treadmill
Description: Participants randomized to the Control group will complete high intensity gait training on a treadmill.
Study NCT04340063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training performed in a Movement Amplification Environment
Description: The Experimental group will perform all gait training within the movement amplification environment. To create the movement amplification environment, the investigators have constructed a cable-driven robot, the Agility Trainer. The Agility Trainer applies small forces to the pelvis that increase the difficulty to maintain forward walking
Study NCT04017741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Depo-Medrone and Lidocaine
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm.
Study NCT04017741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combined Depo-Medrone and Lidocaine
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm.
Study NCT04017741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
Study NCT04017741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
Study NCT01544491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
Study NCT01544491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
Study NCT04475848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6953958
Description: Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD).
Study NCT04475848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: A placebo will be administered in an adaptive manner. The starting dose is planned to be 5 mg.~Part 2: The starting dose is planned to be 45 mg.
Study NCT02544984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
Study NCT04953455 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT02775851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT02775851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02775851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02775851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI
Study NCT02775851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03739983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Renewal Program
Description: Therapeutic vibrating wand.
Study NCT02775851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT02355977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline
Description: Periocline dental ointment
Study NCT02355977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surface and root planning
Description: surface and root planning
Study NCT04077476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Yoga + Facebook
Description: Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
Study NCT04077476 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Yoga
Description: Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
Study NCT04036643 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
Study NCT04252833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-044
Description: CT-044 HCl is a reactive species decomposition accelerant
Study NCT01536275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition
Description: Withholding parenteral nutrition during the first 7 days of ICU stay
Study NCT02088515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Study NCT02088515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT02088515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT02088515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03917433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.